8:25 am Chair’s Opening Remarks

8:30 am Panel Discussion: How Can Investors & Companies Work Together to Save GBM Funding?


  • Addressing how to attract investment for novel therapies which are not yet clinically proven
  • Understanding how to gain support for novel strategies, including combination therapy trials
  • Comparing the two main sources of funding- public vs private funding

Speakers To Be Announced

9:10 am
Learning First Hand Advice from Experts Exploring the Current Landscape of GBM Precision Therapeutics

9:45 am Using the Antigenic Signature of Self-renewing GBM Cells to Target Low & High Mutational Tumor Burden


  • Autologous dendritic cells loaded with autologous tumor antigens from self-renewing tumor initiating cells as personal therapeutic cancer vaccines
  • Lessons learned from a single-arm phase 2 trial in primary GBM
  • Randomized, blinded phase 3 trial in primary GBM

10:15 am Morning Break & Networking

11:00 am Development of Imvax’s IGV-001 for the Treatment of Newly Diagnosed Glioblastoma Utilizes a Personalized Tumor-Derived Immunotherapy Platform Exploiting the Full Antigenic Signature of GBM


  • IGV-001, an autologous cell Immunotherapy with antisense oligonucleotide (IMV-001) targeting IGF1R, is a biologic-device combination product developed from Imvax’s proprietary platform, GoldspireTM
  • Imvax’s GBM program builds on published Phase 1b data to leverage this cell-based autologous immunotherapy to combat the immunosuppressive GBM TME
  • A randomized, multicenter, double-blind, placebo-controlled, Phase 2b study assessing the safety and efficacy of IGV-001 in newly diagnosed patients with glioblastoma enrolled the first patient in March 2023
  • The Phase 2b trial will enroll up to 93 participants in a 2:1 randomization across approximately 25 sites in the U.S. and is on schedule to complete enrollment in the first half of 2024
  • The primary endpoint of the study is median progression-free survival (PFS) and key secondary endpoints include overall survival and safety, with PFS data expected to be available in mid-2025

11:30 am Biopharma Insights Within the GBM Space – GBM Precision Discovery Strategy at Bristol-Myers Squibb


  • Overview of the ongoing R&D work in GBM at Bristol-Myers Squibb
  • Leveraging clinical datasets to understand the disease
  • Implementing a precision discovery strategy to succeed

12:00 pm Targeting MAPK Signalling Pathways to Stop GBM Tumor Cell Proliferation

  • Zane Yang Chief Medical Officer, ABM Therapeutics


  • Introducing a new generation of brain penetrant BRAF inhibitors for GBM
  • ABM-1310 for BRAF v600-mutant GBM tumors- Phase I study
  • Clinical evidence of ABM-1310 in high grade gliomas including GBM

12:30 pm Lunch

1:25 pm
Exploring the Current Landscape of GBM Precision Therapeutics – Hear First Hand Advice from Experts

1:30 pm Leveraging Immune Checkpoint Inhibitors to Target Multiple Tumor Microenvironment Cell Population

  • Jing Watnick Founder & Chief Operating Officer, Vigeo Therapeutics


  • Novel biological activity stimulates thrombospondin-1 expression to target myeloid and inflammatory cells in the TME via CD36 and CD47
  • Understand the influence of the TME and peripheral immune cells in GBM IO treatment
  • Discuss promising biomarkers for responses to immune checkpoint inhibitors

2:00 pm Leveraging Engineered Gamma-Delta T Cells for Enhanced Tumor Cell Destruction in GBM


  • Overcoming challenges of antigen selection with engineered T-cells for GBM tumor destruction
  • Using gamma-delta T cells to combine an innate and adaptive immune response in GBM
  • Determining the best combinatorial approach for cell therapy in solid tumors

2:30 pm Harnessing Oncolytic Viruses to Surpass the ‘Cold’ Tumor Microenvironment


  • Design of novel oncolytic viruses to inhibit the immunosuppressive microenvironment, expose multiple tumor antigens and selectively kill cancer cells for an individualized immune response
  • Evaluate viral immunotherapy showing promise in treatment resistant high-grade glioma
  • Review clinical and biomarker data from a phase 1 study of CAN-3110 in recurrent high grade glioma 

3:00 pm Afternoon Break

3:05 pm
Exploring the Current Landscape of GBM Precision Therapeutics – Hear First Hand Advice from Experts

3:30 pm Targeted DNA Modification: A New Paradigm to Exploit DDR Defects in Glioma and Beyond…


  • Discuss Modifi Bio’s development candidate which selectively targets MGMT-deficient cancers
  • Review data suggesting efficacy of these molecules across a range of brain tumor models, as a monotherapy and in combination with other agents
  • Highlights of Modifi’s biomarker strategy to enrich for MGMT- gliomas with acquired MMR mutations in a phase 0/I trial

4:00 pm EGFRvIII-Targeted Alpha Therapy for Precision Cancer Cell Destruction in GBM


  • What is targeted alpha therapy (TAT) and theranostics?
  • Advantages of TAT for treatment of GBM
  • Preclinical evaluation of an EGFRvIII-targeted alpha therapy in PDX models with varying degrees of BBB permeability

4:30 pm Reinventing Radioligand Therapy for Targeted Tumor Cell Destruction

  • Daniela Niepel Executive Director - Global Medical Affairs, Novartis


  • The pipeline of targeted radiotherapy approaches for GBM
  • Novel methods of overcoming existing barriers to targeted radiotherapy
  • An update on present and upcoming Novartis research in GBM

5:00 pm Delaying Disease Progression & Boosting Therapeutic Efficacy By Targeting the DNA Damage Response


  • Reviewing the landscape of DDR targeted approaches
  • Targeting DDR mechanisms to enhance efficacy of other treatments
  • Tackling the incorporation of DDR agents from a regulatory standpoint

5:30 pm Chair’s Closing Remarks